AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$MRNA

Mock James M sold $4.7M of MRNA

Mock James M (Chief Financial Officer) sold 34,836 shares of Moderna, Inc. (MRNA) at $134.49 ($4.69M total) across 2 trades on 2026-09-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mock James M
Published Sep 14, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MRNA
Bearish
medium confidence
Mentioned
$MRNA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRNABearishLow
01

Why it matters

The disclosed sale adds new information about insider activity, but the amount is modest relative to market cap.

02

Market read

Provides fresh data for traders tracking insider activity; limited immediate trading impetus.

03

What to watch

The 10b5‑1 plan pre‑arranged nature reduces speculation about timing motives.

Relevance 5/10Novelty 6/10Timing: filing date 2026‑09‑14, reflects sale on 2026‑09‑10

Background

Form 4 filings disclose insider transactions; CFO sales are closely monitored for potential signals.

Company-level read

Ticker impact

$MRNABearishMedium confidence
Context

CFO James M. Mock sold 34,836 shares for $4.7M via a 10b5‑1 plan on 2026‑09‑10.

Expected impact

Possible modest downside of 1‑2% over the next few days.

Evidence & confidence

Insider sales by a senior officer are material, especially when executed through a pre‑arranged plan at a high price, suggesting the insider is cashing out.

Market effects

Sector

May weigh on biotech sector sentiment as CFO insider sales are watched closely.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond Moderna shareholders.

Counterpoint

What could challenge this read

The sale could be routine cash diversification; the high price may indicate confidence in near‑term valuation.

Key entities

  • Person
    James M. Mock

    Chief Financial Officer of Moderna, Inc.

  • Company
    Moderna, Inc.

    Biotech firm developing mRNA therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MRNA insider trading history →

Related articles

OCT 15
$MRNAMed

Moderna Stock Jumps 4.5% as Major Cancer Vaccine Catalyst Approaches

Moderna (MRNA) shares rose 4.5% as investors await detailed results from a Phase 3 cancer trial with Merck (MRK). The trial, involving 1,137 patients, showed the treatment reduced cancer recurrence. Results will be presented on October 24. Moderna reported a Q2 net loss of $782 million. Barclays estimates potential $3 billion annual melanoma sales by 2035, split equally with Merck.

tipranks.com6 min
OCT 15
$MRNAMed

Moderna (MRNA) Shares Surge on Cancer Vaccine Data Ahead of Late

Moderna (MRNA) shares rose 38% since late September ahead of a presentation on late-stage trial data for its cancer vaccine, developed with Merck (MRK). The rally follows a 170% surge after positive Phase 3 melanoma trial results in August. Moderna's P/S ratio is 41.76, significantly higher than its historical median of 8.48, reflecting market growth expectations despite its unprofitability. Insider activity shows no purchases and $64.6M in sales over the past year.

gurufocus.com6 min
OCT 15
$MRNAHigh

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

Moderna's stock rose 658.2% year-to-date, reaching $223.60 premarket. The surge followed positive late-stage trial results for its cancer vaccine, developed with Merck. Analysts' price targets are below current levels, with a consensus at $122.67. Moderna reports Q3 earnings on November 6, with revenue and cash flow expectations to be revealed. The stock trades at 38.75 times trailing sales, raising valuation concerns.

247wallst.com2 min
OCT 15
$MRNAMed

MRNA Maintains Neutral Rating -- Price Target Raised to $137

Goldman Sachs maintained a Neutral rating on Moderna (MRNA) but raised its price target to $137 from $120. GuruFocus values MRNA at $23.84, suggesting it is 849.2% overvalued. The company has a GF Score of 54/100, with strengths in financial stability but weaknesses in profitability and valuation. Insider selling totaled $49.18M over the past three months.

gurufocus.com2 min
OCT 14
$MRNAHigh

MRNA Stock Surges On Cancer Vaccine Catalysts And Nasdaq-100 Move

Moderna Inc. (MRNA) shares rose 4.13% on October 14, 2026, driven by optimism around its mRNA cancer vaccine pipeline and inclusion in the Nasdaq-100 Index. The company reported $143M in revenue and a net loss of $782M for the latest quarter, with $5.1B in cash reserves. Analysts have adjusted price targets, with Bank of America raising its target to $200 and Morgan Stanley to $95, both maintaining cautious ratings. The next key catalyst is Moderna's Q3 2026 earnings report on November 6, 2026.

timothysykes.com3 min